MedPath

Caffeine

Generic Name
Caffeine
Brand Names
Anacin, Arthriten Inflammatory Pain, Ascomp, Bc Arthritis, Bc Original Formula, Cafcit, Diurex, Dvorah, Esgic, Exaprin, Excedrin, Excedrin Tension Headache, Fioricet, Fioricet With Codeine, Fiorinal, Goody's Extra Strength, Goody's Headache Relief Shot, Goody's PM, Midol Complete, Midol Cramps & Bodyaches, Migergot, Norgesic, Norgesic Forte, Orbivan, Orphengesic, Pamprin Max Formula, Peyona, Stanback Headache Powder Reformulated Jan 2011, Trezix, Trianal, Trianal C, Triatec, Triatec-8, Vanatol, Vanatol S, Vanquish, Vivarin, Peyona (previously Nymusa), Gencebok
Drug Type
Small Molecule
Chemical Formula
C8H10N4O2
CAS Number
58-08-2
Unique Ingredient Identifier
3G6A5W338E
Background

Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to Theophylline and Theobromine. It can be sourced from coffee beans, but also occurs naturally in various teas and cacao beans, which are different than coffee beans. Caffeine is also used in a variety of cosmetic products and can be administered topically, orally, by inhalation, or by injection.

The caffeine citrate injection, used for apnea of the premature newborn, was initially approved by the FDA in 1999. According to an article from 2017, more than 15 million babies are born prematurely worldwide. This correlates to about 1 in 10 births. Premature birth can lead to apnea and bronchopulmonary dysplasia, a condition that interferes with lung development and may eventually cause asthma or early onset emphysema in those born prematurely. Caffeine is beneficial in preventing and treating apnea and bronchopulmonary dysplasia in newborns, improving the quality of life of premature infants.

Indication

Caffeine is indicated for the short term treatment of apnea of prematurity in infants and off label for the prevention and treatment of bronchopulmonary dysplasia caused by premature birth. In addition, it is indicated in combination with sodium benzoate to treat respiratory depression resulting from an overdose with CNS depressant drugs. Caffeine has a broad range of over the counter uses, and is found in energy supplements, athletic enhancement products, pain relief products, as well as cosmetic products.

Associated Conditions
Acute Pain, Chronic Lung Disease of Prematurity, Common Cold, Dyspepsia, Fatigue, Fever, Flu caused by Influenza, Headache, Menstrual Pain, Myalgia, Pain, Pain caused by Rheumatism, Primary apnea of premature newborns, Respiratory Depression, Somnolence, Tension Headache, Toothache, Under-eyes Dark Circles, Vascular Headaches, Moderate Pain
Associated Therapies
Analgesia, Antacid therapy, Athletic Performance

The Impact of Caffeine on Cognition in Schizophrenia

Not Applicable
Completed
Conditions
Schizophrenia
Caffeine
Interventions
Drug: Placebo
First Posted Date
2016-07-14
Last Posted Date
2022-11-15
Lead Sponsor
Nova Scotia Health Authority
Target Recruit Count
24
Registration Number
NCT02832401
Locations
🇨🇦

BIOTIC Neuroimaging Laboratory, Halifax, Nova Scotia, Canada

This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis

First Posted Date
2016-05-13
Last Posted Date
2017-09-25
Lead Sponsor
AbbVie
Target Recruit Count
21
Registration Number
NCT02772601
Locations
🇩🇪

Boehringer Ingelheim Investigational Site, Berlin, Germany

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

Phase 4
Withdrawn
Conditions
Colitis, Ulcerative
Crohn Disease
Interventions
First Posted Date
2016-05-03
Last Posted Date
2020-10-27
Lead Sponsor
Takeda
Registration Number
NCT02760615
Locations
🇺🇸

WCCT, Cypress, California, United States

🇺🇸

QPS MRA, Miami, Florida, United States

Body Composition Changes With Albuterol and Caffeine Versus Placebo in Adolescents

Not Applicable
Completed
Conditions
Pediatric Obesity
Interventions
Drug: Placebo
Behavioral: Family weight management counseling
First Posted Date
2016-04-15
Last Posted Date
2019-10-08
Lead Sponsor
Pennington Biomedical Research Center
Target Recruit Count
12
Registration Number
NCT02740660
Locations
🇺🇸

Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States

Pharmacokinetic Drug-Drug Interaction Study of Rucaparib

First Posted Date
2016-04-15
Last Posted Date
2023-06-09
Lead Sponsor
pharmaand GmbH
Target Recruit Count
17
Registration Number
NCT02740712
Locations
🇵🇱

BioVirtus Research Site, Kajetany, Mokra 7, Poland

🇵🇱

Zachodniopomorskie Centrum Onkologii Centrum Innowacji, Szczecin, Poland

🇵🇱

Med Polonia, Poznan, Poland

Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin

First Posted Date
2016-02-18
Last Posted Date
2017-11-24
Lead Sponsor
Tobira Therapeutics, Inc.
Target Recruit Count
36
Registration Number
NCT02685462

Prophylactic Versus Therapeutic Caffeine for Apnea of Prematurity

Not Applicable
Completed
Conditions
Apnea
Interventions
First Posted Date
2016-02-09
Last Posted Date
2021-03-16
Lead Sponsor
Mansoura University Children Hospital
Target Recruit Count
180
Registration Number
NCT02677584
Locations
🇪🇬

Mansoura University Children Hospital, Mansoura, El Dakahlya, Egypt

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

Phase 1
Completed
Conditions
Amyotrophic Lateral Sclerosis
Interventions
First Posted Date
2016-01-14
Last Posted Date
2020-08-06
Lead Sponsor
Genentech, Inc.
Target Recruit Count
54
Registration Number
NCT02655614
Locations
🇺🇸

Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

🇺🇸

Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States

🇺🇸

Forbes Norris Mda/als Ctr; Research Center, San Francisco, California, United States

and more 7 locations

Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)

First Posted Date
2016-01-06
Last Posted Date
2016-08-22
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
14
Registration Number
NCT02647086
Locations
🇺🇸

Regeneron Study Site, Raleigh, North Carolina, United States

To Determine Blood Concentrations of Ibuprofen and Caffeine in a Tablet Against Ibuprofen Alone From Another Tablet

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2015-12-14
Last Posted Date
2017-05-05
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
36
Registration Number
NCT02629354
Locations
🇿🇦

Boehringer Ingelheim Investigational Site, Bloemfontein, South Africa

© Copyright 2025. All Rights Reserved by MedPath